| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-05-29 13:28:52 -0600 |
| HMDB ID |
HMDB00742 |
| Secondary Accession Numbers |
|
| Metabolite Identification |
| Common Name |
Homocysteine |
| Description |
Homocysteine is a sulfur-containing amino acid that arises during methionine metabolism. Although its concentration in plasma is only about 10 micromolar (uM), even moderate hyperhomocysteinemia is associated with increased incidence of cardiovascular disease and Alzheimer's disease. Elevations in plasma homocysteine are commonly found as a result of vitamin deficiencies, polymorphisms of enzymes of methionine metabolism, and renal disease. Pyridoxal, folic acid, riboflavin, and Vitamin B(12) are all required for methionine metabolism, and deficiency of each of these vitamins result in elevated plasma homocysteine. A polymorphism of methylenetetrahydrofolate reductase (C677T), which is quite common in most populations with a homozygosity rate of 10-15 %, is associated with moderate hyperhomocysteinemia, especially in the context of marginal folate intake. Plasma homocysteine is inversely related to plasma creatinine in patients with renal disease. This is due to an impairment in homocysteine removal in renal disease. The role of these factors, and of modifiable lifestyle factors, in affecting methionine metabolism and in determining plasma homocysteine levels is discussed. Homocysteine is an independent cardiovascular disease (CVD) risk factor modifiable by nutrition and possibly exercise. Homocysteine was first identified as an important biological compound in 1932 and linked with human disease in 1962 when elevated urinary homocysteine levels were found in children with mental retardation. This condition, called homocysteinuria, was later associated with premature occlusive CVD, even in children. These observations led to research investigating the relationship of elevated homocysteine levels and CVD in a wide variety of populations including middle age and elderly men and women with and without traditional risk factors for CVD. (PMID 17136938 , 15630149 ). |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (+-)-homocysteine
- (S)-2-amino-4-mercapto-Butanoate
- (S)-2-amino-4-mercapto-Butanoic acid
- 2-Amino-4-mercapto-Butanoate
- 2-Amino-4-mercapto-Butanoic acid
- 2-Amino-4-mercapto-Butyric acid
- 2-Amino-4-mercapto-DL-Butyrate
- 2-Amino-4-mercapto-DL-Butyric acid
- 2-Amino-4-mercaptobutyric acid
- 2-Amino-4-sulfanylbutanoate
- 2-Amino-4-sulfanylbutanoic acid
- D,L-Homocysteine
- DL-2-amino-4-mercapto-Butyric acid
- DL-2-Amino-4-mercaptobutyric acid
- DL-Homocysteine
- DL-homocysteine (free base)
- HCY
- Homo-CYS
- Homocysteine
- L-2-Amino-4-mercapto-Butyric acid
- L-Homocysteine
- Usaf B-12
|
| Chemical Formula |
C4H9NO2S |
| Average Molecular Weight |
135.185 |
| Monoisotopic Molecular Weight |
135.035399227 |
| IUPAC Name |
2-amino-4-sulfanylbutanoic acid |
| Traditional IUPAC Name |
homocysteine |
| CAS Registry Number |
454-29-5 |
| SMILES |
NC(CCS)C(O)=O |
| InChI Identifier |
InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7) |
| InChI Key |
FFFHZYDWPBMWHY-UHFFFAOYSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Amino Acids, Peptides, and Analogues |
| Class |
Amino Acids and Derivatives |
| Sub Class |
Alpha Amino Acids and Derivatives |
| Other Descriptors |
- Aliphatic Acyclic Compounds
- amino acid zwitterion(ChEBI)
|
| Substituents |
- Alkylthiol
- Carboxylic Acid
- Primary Aliphatic Amine (Alkylamine)
- Thiol (Sulfanyl Compound)
|
| Direct Parent |
Alpha Amino Acids and Derivatives |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Component of Glycine, serine and threonine metabolism
- Component of Methionine metabolism
- Component of Selenoamino acid metabolism
- Component of Ubiquinone biosynthesis
- Essential amino acid
- Waste products
|
| Application |
Not Available
|
| Cellular locations |
- Cytoplasm (predicted from logP)
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
232 - 233 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
148 mg/mL |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
|
| Biological Properties |
| Cellular Locations |
- Cytoplasm (predicted from logP)
|
| Biofluid Locations |
- Blood
- Cerebrospinal Fluid (CSF)
- Urine
|
| Tissue Location |
- Muscle
- Fibroblasts
- Intestine
- Neuron
- Pancreas
- Placenta
- Kidney
- Liver
- Brain
- Adipose Tissue
- Nerve Cells
- Platelet
- Artery
|
| Pathways |
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
9.4 (7.3-16.2) uM |
Adult (>18 years old) |
Not Specified |
Normal
|
|
| Blood |
Detected and Quantified |
|
9.8 (7.6-14.9) uM |
Adult (>18 years old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
5.00 +/- 1.6 uM |
Infant (0-1 year old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
10.4 +/- 2.3 uM |
Children (1-13 year old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
9.00 +/- 2.2 uM |
Adolescent (13-18 years old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
9.00 +/- 2.00 uM |
Adult (>18 years old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
6.00 (4.8-7.40) uM |
Adult (>18 years old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
9.11 +/- 2.99 uM |
Adult (>18 years old) |
Not Specified |
Normal
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.09 (0.06-0.16) uM |
Adult (>18 years old) |
Not Specified |
Normal
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
20.7 +/- 1.7 uM |
Elderly (>65 years old) |
Both |
Normal
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.057 +/- 0.035 uM |
Adult (>18 years old) |
Not Specified |
Normal
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.12 +/- 0.08 uM |
Elderly (>65 years old) |
Not Specified |
Normal
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.15 +/- 0.07 uM |
Adult (>18 years old) |
Not Specified |
Normal
|
|
| Urine |
Detected and Quantified |
|
1.1 (0.6-1.74) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal
|
|
| Urine |
Detected and Quantified |
|
2.00 +/- 1.65 umol/mmol creatinine |
Infant (0-1 year old) |
Male |
Normal
|
|
| Urine |
Detected and Quantified |
|
1.5 +/- 0.69 umol/mmol creatinine |
Children (1-13 year old) |
Male |
Normal
|
|
| Urine |
Detected and Quantified |
|
1.78 +/- 0.73 umol/mmol creatinine |
Adolescent (13-18 years old) |
Male |
Normal
|
|
| Urine |
Detected and Quantified |
|
1.95 +/- 1.47 umol/mmol creatinine |
Adult (>18 years old) |
Male |
Normal
|
|
|
| Abnormal Concentrations |
|
| Blood |
Detected and Quantified |
|
12.9 (8.2-28.2) uM |
Adult (>18 years old) |
Not Specified |
Dementia (Alzheimer's and non-Alzheimer's)
|
|
| Blood |
Detected and Quantified |
|
10.7 (7.6-14.4) uM |
Adult (>18 years old) |
Not Specified |
Multiple sclerosis
|
|
| Blood |
Detected and Quantified |
|
10.2 (7.0-17.4) uM |
Adult (>18 years old) |
Not Specified |
Stroke
|
|
| Blood |
Detected and Quantified |
|
11.9 (7.0-19.1) uM |
Adult (>18 years old) |
Not Specified |
Peripheral neuropathy
|
|
| Blood |
Detected and Quantified |
|
21.0 (18.5-25.7) uM |
Adult (>18 years old) |
Both |
Chronic renal failure
|
|
| Blood |
Detected and Quantified |
|
25.5 (16.9-32.6) uM |
Adult (>18 years old) |
Both |
Continuous ambulatory peritoneal dialysis (CAPD)
|
|
| Blood |
Detected and Quantified |
|
29.7 (25.7-38.2) uM |
Adult (>18 years old) |
Both |
Hemodialysis
|
|
| Blood |
Detected and Quantified |
|
12.5 +/- 5.0 uM |
Adult (>18 years old) |
Both |
Sickle cell anemia
|
|
| Blood |
Detected and Quantified |
|
125.00 (50.00-200.00) uM |
Adult (>18 years old) |
Both |
Cystathionine beta-synthase deficiency
|
|
| Blood |
Detected and Quantified |
|
9.22 +/- 1.81 uM |
Adult (>18 years old) |
Not Specified |
Cruetzfeldt-Jakob disease
|
|
| Blood |
Detected and Quantified |
|
15.1 uM |
Adult (>18 years old) |
Both |
Parkinson's disease
|
|
| Blood |
Detected and Quantified |
|
13.94 +/- 3.47 uM |
Adult (>18 years old) |
Both |
Amyotrophic lateral sclerosis
|
|
| Blood |
Detected and Quantified |
|
15.75 +/- 5.75 uM |
Adult (>18 years old) |
Both |
Progressive supranuclear palsy
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.08 (0.05-0.16) uM |
Adult (>18 years old) |
Not Specified |
Multiple sclerosis
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.08 (0.06-0.15) uM |
Adult (>18 years old) |
Not Specified |
Stroke
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.11 (0.07-0.18) uM |
Adult (>18 years old) |
Not Specified |
Peripheral neuropathy
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.216 +/- 0.122 uM |
Adult (>18 years old) |
Not Specified |
Alzheimer's disease
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.12 +/- 0.062 uM |
Elderly (>65 years old) |
Not Specified |
Alzheimer's disease
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.10 (0.06–0.32) uM |
Adult (>18 years old) |
Not Specified |
Dementia (Alzheimer's and non-Alzheimer's)
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
14.2 +/- 1.7 uM |
Elderly (>65 years old) |
Not Specified |
Alzheimer's disease
|
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.13 +/- 0.03 uM |
Adult (>18 years old) |
Not Specified |
Cruetzfeldt-Jakob disease
|
|
|
| Associated Disorders and Diseases |
| Disease References |
| Creutzfeldt-Jakob disease |
- Bleich S, Otto M, Zerr I, Kropp S, Kretzschmar HA, Wiltfang J: Creutzfeldt-Jakob disease and homocysteine levels in plasma and cerebrospinal fluid. Gerontology. 2005 Mar-Apr;51(2):142-4.
Pubmed: 15711082
- [No authors listed]
Pubmed: 115711082
|
| Dementia |
- Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.
Pubmed: 17384003
|
| Alzheimer's disease |
- Selley ML, Close DR, Stern SE: The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging. 2002 May-Jun;23(3):383-8.
Pubmed: 11959400
- Serot JM, Barbe F, Arning E, Bottiglieri T, Franck P, Montagne P, Nicolas JP: Homocysteine and methylmalonic acid concentrations in cerebrospinal fluid: relation with age and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1585-7.
Pubmed: 16227558
|
| Sickle cell anemia |
- van der Dijs FP, Schnog JJ, Brouwer DA, Velvis HJ, van den Berg GA, Bakker AJ, Duits AJ, Muskiet FD, Muskiet FA: Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol. 1998 Nov;59(3):192-8.
Pubmed: 9798656
|
| Multiple sclerosis |
- Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.
Pubmed: 17384003
|
| Stroke |
- Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.
Pubmed: 17384003
|
| Peripheral neuropathy |
- Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.
Pubmed: 17384003
|
| Chronic renal failure |
- McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST: Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 2001 Jun;59(6):2267-72.
Pubmed: 11380830
|
| Continuous ambulatory peritoneal dialysis |
- McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST: Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 2001 Jun;59(6):2267-72.
Pubmed: 11380830
|
| Hemodialysis |
- McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST: Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 2001 Jun;59(6):2267-72.
Pubmed: 11380830
|
| Homocystinuria |
|
|
| Parkinson's disease |
- Levin J, Botzel K, Giese A, Vogeser M, Lorenzl S: Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dement Geriatr Cogn Disord. 2010 Jul;29(6):553-9. Epub 2010 Jul 3.
Pubmed: 20606437
|
|
| Associated OMIM IDs |
|
| External Links |
| DrugBank ID |
Not Available |
| DrugBank Metabolite ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB001491 |
| KNApSAcK ID |
C00001365  |
| Chemspider ID |
757  |
| KEGG Compound ID |
C05330  |
| BioCyc ID |
HOMO-CYS  |
| BiGG ID |
45588  |
| Wikipedia Link |
Homocysteine  |
| NuGOwiki Link |
HMDB00742  |
| Metagene Link |
HMDB00742  |
| METLIN ID |
3256  |
| PubChem Compound |
778  |
| PDB ID |
Not Available |
| ChEBI ID |
17230  |
| References |
| Synthesis Reference |
Karrenbauer, Michael; Kleemann, Axel; Luessling, Theodor; Schaefer, Fritz. D,L-Homocysteine (I). Ger. (1984), 4 pp. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Yu CK, Lakasing L, Papageorghiou AT, Spencer K, Nicolaides KH: Uterine artery Doppler and mid-trimester maternal plasma homocysteine in subsequent pre-eclampsia. J Matern Fetal Neonatal Med. 2004 Aug;16(2):134-9.
Pubmed: 15512726
- Giladi N, Mordechovich M, Gruendlinger L, Shabtai H, Merims D, Naor S, Baltadzhieva R, Hausdorff JM, Gur AY, Bornstein NM: "Brain Screen": A self-referral, screening program for strokes, falls and dementia risk factors. J Neurol. 2006 Mar;253(3):307-15. Epub 2005 Oct 10.
Pubmed: 16208527
- Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C: Hyperhomocysteinemia in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2004 Aug;89(8):3745-51.
Pubmed: 15292300
- Laxdal E, Eide GE, Amundsen SR, Dregelid EB, Pedersen G, Jonung T, Aune S: Homocysteine levels, haemostatic risk factors and restenosis after carotid thrombendarterectomy. Eur J Vasc Endovasc Surg. 2004 Sep;28(3):323-8.
Pubmed: 15288638
- Akoglu B, Wondra K, Caspary WF, Faust D: Determinants of fasting total serum homocysteine levels in liver transplant recipients. Exp Clin Transplant. 2006 Jun;4(1):462-6.
Pubmed: 16827644
- Krantz JS, Mack WJ, Hodis HN, Liu CR, Liu CH, Kaufman FR: Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. J Pediatr. 2004 Oct;145(4):452-7.
Pubmed: 15480366
- Selley ML, Close DR, Stern SE: The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging. 2002 May-Jun;23(3):383-8.
Pubmed: 11959400
- Serot JM, Barbe F, Arning E, Bottiglieri T, Franck P, Montagne P, Nicolas JP: Homocysteine and methylmalonic acid concentrations in cerebrospinal fluid: relation with age and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1585-7.
Pubmed: 16227558
- Hershcovici T, Schechner V, Orlin J, Harell D, Beigel Y: Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J Clin Apher. 2004;19(2):90-7.
Pubmed: 15274202
- Muller T, Renger K, Kuhn W: Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol. 2004 May;61(5):657-60.
Pubmed: 15148140
- Eskes TK: Homocysteine and human reproduction. Clin Exp Obstet Gynecol. 2000;27(3-4):157-67.
Pubmed: 11214939
- Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Fodinger M, Horl WH, Sunder-Plassmann G: Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol. 2005 Jan;16(1):255-60. Epub 2004 Nov 24.
Pubmed: 15563562
- Park BH, Kim YJ, Park JS, Lee HY, Ha EH, Min JW, Park HS: [Folate and homocysteine levels during pregnancy affect DNA methylation in human placenta] J Prev Med Pub Health. 2005 Nov;38(4):437-42.
Pubmed: 16358830
- Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW, Zhang K, Kaufman RJ, Austin RC: TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the cevelopment of atherosclerosis in hyperhomocysteinemia. J Biol Chem. 2003 Aug 8;278(32):30317-27. Epub 2003 May 8.
Pubmed: 12738777
- Schafer SA, Mussig K, Stefan N, Haring HU, Fritsche A, Balletshofer BM: Plasma homocysteine concentrations in young individuals at increased risk of type 2 diabetes are associated with subtle differences in glomerular filtration rate but not with insulin resistance. Exp Clin Endocrinol Diabetes. 2006 Jun;114(6):306-9.
Pubmed: 16868889
- Tchantchou F: Homocysteine increase folate oxidative brain homocysteine metabolism and various consequences of folate deficiency. J Alzheimers Dis. 2006 Aug;9(4):421-7.
Pubmed: 16917151
- Siroka R, Trefil L, Rajdl D, Racek J, Rusnakova H, Cibulka R, Eiselt J, Filipovsky J: Asymmetric dimethylarginine, homocysteine and renal function--is there a relation? Clin Chem Lab Med. 2005;43(10):1147-50.
Pubmed: 16197312
- Onalan R, Onalan G, Gunenc Z, Karabulut E: Combining 2nd-trimester maternal serum homocysteine levels and uterine artery Doppler for prediction of preeclampsia and isolated intrauterine growth restriction. Gynecol Obstet Invest. 2006;61(3):142-8. Epub 2005 Dec 20.
Pubmed: 16374017
- Robinson G, Narasimhan S, Weatherall M, Beasley R: Raised plasma homocysteine levels in alcoholism: increasing the risk of heart disease and dementia? N Z Med J. 2005 Jun 3;118(1216):U1490.
Pubmed: 15937525
- Gulsen M, Yesilova Z, Bagci S, Uygun A, Ozcan A, Ercin CN, Erdil A, Sanisoglu SY, Cakir E, Ates Y, Erbil MK, Karaeren N, Dagalp K: Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2005 Sep;20(9):1448-55.
Pubmed: 16105135
- Joubert LM, Manore MM: Exercise, nutrition, and homocysteine. Int J Sport Nutr Exerc Metab. 2006 Aug;16(4):341-61.
Pubmed: 17136938
- Brosnan JT: Homocysteine and cardiovascular disease: interactions between nutrition, genetics and lifestyle. Can J Appl Physiol. 2004 Dec;29(6):773-80.
Pubmed: 15630149
|